{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:49:10Z","timestamp":1792756150055,"version":"4.5.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1097\/ico.0b013e318159019f","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T05:35:33Z","timestamp":1236231333000},"page":"142-147","source":"Crossref","is-referenced-by-count":114,"title":["Subconjunctival Bevacizumab Injection for Corneal Neovascularization"],"prefix":"10.1097","volume":"27","author":[{"given":"Irit","family":"Bahar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Kaiserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"McAllum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rootman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Slomovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210204","first-page":"91","article-title":"Factors affecting the outcome of corneal transplantation.","volume":"63","author":"Coster","year":"1981","journal-title":"Ann R Coll Surg Engl"},{"key":"R4-3-20210204","first-page":"1625","article-title":"A model of angiogenesis in the mouse cornea.","volume":"37","author":"Kenyon","year":"1996","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R5-3-20210204","first-page":"961","article-title":"Vascular endothelial growth factor (rh VEGF165) stimulates direct angiogenesis in the rabbit cornea.","volume":"8","author":"Phillips","year":"1994","journal-title":"In Vivo"},{"key":"R6-3-20210204","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization.","volume":"39","author":"Amano","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R7-3-20210204","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.","volume":"331","author":"Aiello","year":"1994","journal-title":"N Engl J Med"},{"key":"R8-3-20210204","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF00192885","article-title":"Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects.","volume":"73","author":"Battegay","year":"1995","journal-title":"J Mol Med"},{"key":"R9-3-20210204","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1242\/dev.114.2.521","article-title":"Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation.","volume":"114","author":"Breier","year":"1992","journal-title":"Development"},{"key":"R10-3-20210204","first-page":"3974","article-title":"Mechanisms of retinal and choroidal neovascularization.","volume":"35","author":"DAmore","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R11-3-20210204","first-page":"574","article-title":"Vascular endothelial growth factor\/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model.","volume":"145","author":"Miller","year":"1994","journal-title":"Am J Pathol"},{"key":"R12-3-20210204","first-page":"638","article-title":"Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases.","volume":"72","author":"Peer","year":"1995","journal-title":"Lab Invest"},{"key":"R13-3-20210204","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archopht.1996.01100140172010","article-title":"Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate.","volume":"114","author":"Tolentino","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"R14-3-20210204","first-page":"2514","article-title":"Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas.","volume":"41","author":"Philipp","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R15-3-20210204","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"R16-3-20210204","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ophtha.2005.01.043","article-title":"Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.","volume":"112","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmology"},{"key":"R17-3-20210204","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study.","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"key":"R18-3-20210204","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","article-title":"Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R19-3-20210204","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bjo.2005.066431","article-title":"Bevacizumab suppresses choroidal neovascularization caused by pathological myopia.","volume":"89","author":"Nguyen","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R20-3-20210204","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R21-3-20210204","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp068185","article-title":"The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration.","volume":"355","author":"Steinbrook","year":"2006","journal-title":"N Engl J Med"},{"key":"R22-3-20210204","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ophtha.2006.05.070","article-title":"Systemic Bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open label clinical study.","volume":"113","author":"Moshfeghi","year":"2006","journal-title":"Ophthalmology"},{"key":"R23-3-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2006.02.037","article-title":"Intravitreal bevacizumab for the management of choroidal neovascularization in age related macular degeneration.","volume":"142","author":"Bashshur","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R24-3-20210204","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00006982-200603000-00016","article-title":"Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.","volume":"26","author":"Avery","year":"2006","journal-title":"Retina"},{"key":"R25-3-20210204","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006982-200603000-00004","article-title":"Intravitreal Bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"R26-3-20210204","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularization by bevacizumab (Avastin).","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R27-3-20210204","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R28-3-20210204","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1126\/science.2416056","article-title":"A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment.","volume":"230","author":"Crum","year":"1985","journal-title":"Science"},{"key":"R29-3-20210204","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/jop.1994.10.273","article-title":"Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization.","volume":"10","author":"Lepri","year":"1994","journal-title":"J Ocul Pharmacol"},{"key":"R30-3-20210204","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1006\/exer.1993.1177","article-title":"The effect of angiostatic steroids and B-Cyclodextrin tetradecasulfate on corneal neovascularization in the rats.","volume":"57","author":"Proia","year":"1993","journal-title":"Exp Eye Res"},{"key":"R31-3-20210204","first-page":"1588","article-title":"Effects of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat.","volume":"30","author":"Haynes","year":"1989","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R32-3-20210204","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/02713688809031785","article-title":"Modulation of immunogenickeratitis in rabbits by topical administration of inhibitors of lipoxygenase and cyclooxygenase.","volume":"7","author":"Verbey","year":"1988","journal-title":"Curr Eye Res"},{"key":"R33-3-20210204","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/0002-9394(79)90245-9","article-title":"Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas.","volume":"87","author":"Deutsch","year":"1979","journal-title":"Am J Ophthalmol"},{"key":"R34-3-20210204","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/exer.1998.0512","article-title":"The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization.","volume":"67","author":"Benelli","year":"1998","journal-title":"Exp Eye Res"},{"key":"R35-3-20210204","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archopht.1992.01080150103037","article-title":"Suppression of corneal neovascularization with cyclosporine.","volume":"110","author":"Lipman","year":"1992","journal-title":"Arch Ophthalmol"},{"key":"R36-3-20210204","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s004170050387","article-title":"Topical application of methotrexate for inhibition of corneal angiogenesis.","volume":"237","author":"Joussen","year":"1999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R37-3-20210204","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis.","volume":"91","author":"D Amato","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"R38-3-20210204","doi-asserted-by":"crossref","first-page":"9828","DOI":"10.1128\/JVI.75.20.9828-9835.2001","article-title":"Contribution of vascular endothelial growth factor in the neovascularization process during the pathogenesis of herpetic stromal keratitis.","volume":"75","author":"Zheng","year":"2001","journal-title":"J Virol"},{"key":"R39-3-20210204","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/emboj\/19.7.1525","article-title":"Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis.","volume":"19","author":"Binetruy-Tournaire","year":"2000","journal-title":"EMBO J"},{"key":"R40-3-20210204","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1167\/iovs.03-1380","article-title":"Inhibition of lymphagiogenesis and hemangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival.","volume":"45","author":"Cursiefen","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R41-3-20210204","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer.","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"key":"R42-3-20210204","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"R43-3-20210204","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.9-suppl_1-11","article-title":"Targeted therapy of colorectal cancer: clinical experience with bevacizumab.","volume":"9","author":"Fernando","year":"2004","journal-title":"Oncologist"},{"key":"R44-3-20210204","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","article-title":"The international Bevacizumab safety study: using the internet to assess drug safety worldwide.","volume":"90","author":"Fung","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R45-3-20210204","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/01.iae.0000237080.10627.b7","article-title":"Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab.","volume":"26","author":"Kiss","year":"2006","journal-title":"Retina"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00003226-200802000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T17:59:22Z","timestamp":1633197562000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-200802000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e318159019f","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}